Press Releases Enveric Biosciences, Inc.

Equities

ENVB

US29405E2081

Real-time Estimate Cboe BZX Other stock markets 10:20:01 2024-04-29 am EDT			5-day change	1st Jan Change
0.908 ^USD	+1.45%		+6.27%	-29.62%

Mar. 26	Enveric Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 19	Sector Update: Health Care Stocks Rise Late Afternoon	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Enveric Biosciences : Shareholder Meeting - Form 8-K	Mar. 28	PU
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023	Mar. 26	BU
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease	Mar. 19	BU
Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets	Mar. 12	BU
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds	Feb. 29	BU
Medical Breakthrough Stocks Under $1: OCGN, VERO, RSCI, VTAK, ENVB	Feb. 28	AQ
Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property	Feb. 26	AQ
Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property	Feb. 23	BU
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders	Feb. 21	BU
Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series	Jan. 03	BU
Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market	Dec. 29	BU
Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series	Dec. 28	BU
Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373	Dec. 27	BU
Enveric Biosciences to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024”	Dec. 20	BU
Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds	Dec. 05	BU
Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives	Nov. 29	BU
Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference	Nov. 27	AQ
Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry	Nov. 27	BU
Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)	Nov. 24	BU
Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results	Nov. 13	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Enveric Biosciences, Inc.

Equities

ENVB

US29405E2081

Press Releases

Filters